Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,227 recruiting studies in this area right now.
By phase
- Not applicable3,140
- Phase 21,067
- Phase 1822
- Phase 1/Phase 2446
- Phase 3423
- Phase 4236
- Phase 2/Phase 393
Top conditions
- Multiple Sclerosis342
- Multiple Myeloma333
- Asthma194
- Lymphoma182
- Rheumatoid Arthritis142
- Type 1 Diabetes132
- Atopic Dermatitis128
- Systemic Lupus Erythematosus125
- Acute Lymphoblastic Leukemia123
- HIV Infections116
- Chronic Lymphocytic Leukemia100
- Autoimmune Diseases81
- Follicular Lymphoma74
- Diabetes Mellitus, Type 169
- Hodgkin Lymphoma67
- Leukemia64
- Rheumatoid Arthritis (RA)64
- Acute Myeloid Leukemia62
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China91
- National Institute of Allergy and Infectious Diseases (NIAID)90
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris70
- Novartis Pharmaceuticals65
- M.D. Anderson Cancer Center63
- AstraZeneca57
- City of Hope Medical Center46
- Mayo Clinic46
- Memorial Sloan Kettering Cancer Center45
Where studies are running
- California492
- Maryland196
- Alabama176
- Florida143
- Arizona140
- New York122
- Massachusetts119
- Texas118
- Illinois82
- Colorado77
Recruiting studies6,227 total
- NCT07558668RecruitingPhase 1
Testing SYX-5219 for atopic dermatitis in healthy people and patients
This trial tests a new drug called SYX-5219 to see if it is safe and how the body handles it. Part 1 and 2 use healthy volunteers, while Part 3 tests it in people with moderate to severe atopic dermatitis (eczema). The goal is to understand if this drug might help treat eczema symptoms like itching and skin inflammation.
Arkansas City, ArkansasAges 18–65 - NCT07345728Recruiting
BAFFR CAR-T therapy for relapsed B-cell lymphoma
This trial tests a new CAR-T cell treatment that targets a protein called BAFFR on cancer cells. It is for people with B-cell lymphoma that has come back or not responded to previous treatments.
WuhanAges 18–78 - NCT06620770Recruiting
Study on education program for patients on biotherapy
This trial tests whether a therapeutic education program helps people with chronic inflammatory diseases who are on biotherapy injections stick to their treatment and feel better. The program aims to improve compliance and quality of life.
LorientAges 18 years+ - NCT07550673RecruitingPhase 4
Upadacitinib vs. Infliximab for Severe Ulcerative Colitis
This study compares two medications—upadacitinib and infliximab—as second-line treatments for acute severe ulcerative colitis (a serious flare of inflammatory bowel disease). The trial will help doctors understand which treatment works better when standard first-line therapy hasn't controlled the inflammation.
Ankang, ShaanxiAges 18–85 - NCT07565740RecruitingPhase 1
Vaccine plus immunotherapy for newly diagnosed HPV-positive throat cancer
This trial tests a new nasal vaccine combined with an immunotherapy drug (tislelizumab) given before surgery for people with HPV-positive oropharyngeal cancer. The goal is to help the immune system fight the cancer and potentially improve outcomes after surgery.
Chengdu, SichuanAges 18 years+ - NCT07052409Enrolling by invitation
Protecting HIV-exposed infants from severe infections
This trial studies ways to protect babies who were exposed to HIV before birth but are not infected themselves. It aims to find better interventions to prevent severe infections in these infants.
JohannesburgAges 6 months–45 years - NCT07161258RecruitingPhase 2
Fenebrutinib for children with relapsing MS
This study tests a new oral medication called fenebrutinib for children and teenagers with relapsing multiple sclerosis. It aims to find the right dose and see how safe and effective it is compared to standard treatments.
Rosario, Santa Fe ProvinceAges 10–17 - NCT07112144RecruitingPhase 3
DTaP vaccine trial for healthy infants aged 2 months
This trial tests a new vaccine that protects against diphtheria, tetanus, and pertussis (whooping cough). It is for healthy infants who are about 2 months old and live permanently in the area. The goal is to see if the vaccine is safe and works well.
Wenshan Zhuang and Miao Autonomous Prefecture, YunnanAges 2 months–3 months - NCT07185243Recruiting
Study of virus injection plus immunotherapy for advanced solid tumors
This study tests a new combination treatment: a modified virus (hV01) injected directly into a tumor, plus a drug that helps your immune system attack cancer cells (PD-1 inhibitor). It is for people with advanced solid tumors that have not responded to standard therapies.
Xiamen, FujianAges 18–75 - NCT07456358Recruiting
Immune attack targets in brain disease
This study looks at the immune system's role in neurological problems caused by cancer immunotherapy or autoimmune diseases. Researchers will collect spinal fluid to find out which immune targets are involved, which may help improve diagnosis and treatment.
Le Kremlin-BicêtreAges 18 years+ - NCT05718791Recruiting
Testing blood markers to predict graft-versus-host disease
This trial looks at two blood markers to predict the risk of acute graft-versus-host disease after an allogeneic stem cell transplant. If you qualify, your care team may use results to help anticipate and manage complications earlier.
Detroit, MichiganAges 18–80 - NCT06321198Recruiting
Modified stem cells for severe graft-versus-host disease
This trial tests a new type of stem cell therapy (iMSC) for people with steroid-resistant acute graft-versus-host disease (aGVHD), a serious complication after a stem cell transplant. The goal is to see if it's safe and might help control the disease.
Hefei, AnhuiAges 4–70 - NCT07309055RecruitingPhase 3
Study of SHR-1819 injection for teens with severe eczema
This trial tests an injectable medicine called SHR-1819 for teenagers aged 12 to 17 with severe atopic dermatitis (eczema) that has not responded well to creams or other treatments. The goal is to see if it can improve skin symptoms and reduce itching.
Shenyang, LiaoningAges 12–17 - NCT06314230Recruiting
Genomics of chronic kidney transplant failure study
This study looks at how genes affect long-term kidney transplant health. It aims to understand why some transplanted kidneys fail over time, and may help personalize care for transplant recipients.
Westmead, New South WalesAges 18–75 - NCT06694363Recruiting
New test to guide treatment for APDS immune disorder
This study uses a new blood test to find and monitor people with APDS, a rare immune disease, who may be helped by the drug leniolisib. It aims to improve how doctors screen and track treatment response.
BordeauxAges 12 years+ - NCT06691217RecruitingPhase 2
Testing an Anti-Inflammatory Drug for Heart Disease With TET2 Mutation
This study tests whether a medication that blocks inflammation (called an IL-1 beta inhibitor) can reduce blood vessel inflammation in people with both heart disease and a specific genetic change in their blood cells (TET2 mutation). It aims to see if targeting this type of inflammation can help lower heart risks.
Boston, MassachusettsAges 18 years+ - NCT05682482RecruitingPhase 3
Combination T4/T3 vs T4 alone for autoimmune hypothyroid fatigue
This trial compares adding T3 (plus T4) versus taking only T4 to see if it improves severe ongoing tiredness in people with autoimmune hypothyroidism. You would stay on your thyroid medicine plan during the study and be monitored with blood tests and health checks.
Almere StadAges 18 years+ - NCT07043153Recruiting
Predicting lupus disease activity with blood tests
This study looks at whether two blood markers (AGR and PNI) can help track how active lupus is. You may be eligible if you have lupus and are not pregnant or have other serious health conditions.
SohagAges 18 years+ - NCT06093867Recruiting
Tracking lung health after stem cell transplant
This study follows people getting a stem cell transplant to watch for lung problems, like infections or other lung diseases, that can happen after the transplant. The goal is to catch these issues early.
Bethesda, MarylandAges 5–70 - NCT06067555RecruitingEarly Phase 1
Flu vaccine study for healthy adults
This study tests a flu vaccine given just under the skin (intradermal) to see how well it works. It may be a good option if you are a healthy young adult.
New Haven, ConnecticutAges 18–40 - NCT07126028Enrolling by invitation
Quality of life in kids after MIS-C
This study looks at how children feel and live their daily lives after recovering from MIS-C (a severe inflammatory condition linked to COVID-19). It compares them to healthy children of the same age and gender to see if there are any lasting effects.
Rijeka, Primorje-Gorski Kotar CountyAges 1 month–18 years - NCT07039578RecruitingPhase 2
Study of CM336 for light-chain amyloidosis
This trial tests a new injection called CM336 for people with light-chain amyloidosis that has come back or not responded to other treatments. It aims to see if the drug is safe and effective.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07123207Recruiting
Probiotic with infliximab for Crohn's disease
This study is testing whether adding a probiotic (Bacillus subtilis) to standard infliximab treatment can improve outcomes for people with active Crohn's disease. It aims to see if the probiotic helps the medication work better.
Changsha, HunanAges 18–75 - NCT05915442RecruitingPhase 2
Adenosine blocker plus immunotherapy for limited prostate spread
This Phase 2 study tests a medicine that affects “adenosine” signaling along with an immune checkpoint inhibitor (immunotherapy) in men with hormone-sensitive prostate cancer that has spread in only a small, limited way. It aims to stop or slow that limited spread by helping the immune system work better.
New York, New YorkAges 18–99
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,227 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,696 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.